Numiera wins $2.3M NIH grant to push etomoxir into glioblastoma trial

Numiera Therapeutics received a $2.3 million NCI Direct-To-Phase II SBIR grant to advance etomoxir, its orphan-designated CPT1 inhibitor, into early clinical testing for recurrent glioblastoma. The company plans a dose-escalation and window-of-opportunity study to define safety, tumor pharmacology and early efficacy signals.

Why it matters: - Glioblastoma remains one of the deadliest brain cancers, and the grant funds a new targeted approach aimed at tumor metabolism. - The award supports the first clinical development step for etomoxir in glioblastoma, which could open the door to later-phase trials if the study is successful. - The funding adds non-dilutive support for Numiera Therapeutics as it tries to move a first-in-class mitochondrial-targeting drug toward patients.

What happened: - Numiera Therapeutics said it received a $2.3 million National Cancer Institute Direct-To-Phase II SBIR grant. - The award will support an early-phase clinical trial of etomoxir in glioblastoma. - The study will enroll patients with recurrent glioblastoma. - Numiera Therapeutics is based in Denver.

The details: - Etomoxir is described as a first-in-class CPT1 inhibitor with orphan designation. - The planned trial will use a dose-escalation design. - The study will also include a window-of-opportunity component. - The trial aims to identify the maximum tolerated dose in this neuro-oncology population. - The trial will study the drug’s pharmacology in resected brain tumor tissue. - The trial will look for an initial efficacy signal. - Numiera Therapeutics said the program builds on prior Phase I data showing preliminary dose safety. - The SBIR grant award number is 1R44CA310352-01.

Between the lines: - The NCI review panel highlighted the project’s significance, the innovation of targeting fatty acid oxidation, and the team’s record in drug development and glioblastoma. - The panel also cited the trial design as strong and statistically appropriate. - Numiera Therapeutics’ CEO, Izi Stoll, pointed to recent FDA approvals and large transactions in neuro-oncology as evidence that mitochondrial-targeting small molecules are gaining momentum. - That framing suggests Numiera is trying to position etomoxir within a broader wave of metabolism-focused cancer drugs.

What's next: - Numiera Therapeutics will run the clinical study in recurrent glioblastoma patients. - Positive results are expected to support later-phase clinical trials. - The company also says it has additional preclinical validation across five models from five laboratories. - Numiera Therapeutics included a LinkedIn page in the release: the company's announcement.

The bottom line: - The grant gives Numiera Therapeutics the money and validation needed to start clinical testing of etomoxir in a high-risk, high-need brain cancer setting.